A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1140-1146

  Aschele, C ^b   Friso, M L ^a   Pucciarelli, S ^a   Lonardi, S ^a   Sartor, L ^a   Fabris, G ^a   Urso, E D L ^a   Del Bianco, P ^a   Sotti, G ^a   Lise, M ^a   Monfardini, S ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

5 fluorouracil; Neoadjuvant chemoradiation; Oxaliplatin; Phase I II study; Rectal cancer

Indexed keywords

FLUOROURACIL; OXALIPLATIN; POTASSIUM; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DYSESTHESIA; FEASIBILITY STUDY; FEMALE; HUMAN; INCIDENCE; LEUKOPENIA; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECTUM CARCINOMA; RECTUM SURGERY; REHYDRATION; SUBSTITUTION THERAPY; THROMBOCYTOPENIA; VOMITING; COHORT ANALYSIS; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PREOPERATIVE CARE; RECTUM TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RECTAL NEOPLASMS;

EID: 25444503968     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi212     Document Type: Article

References (38)

1. Marijnen CA, Glimelius B. The role of radiotherapy in rectal cancer. Eur J Cancer 2002; 38: 943-952.
2. Heald RJ, Husband EM, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482.
3. Nelson H, Sargent DJ. Refining multimodal therapy for rectal cancer. N Engl J Med 2001; 345: 690-692.
4. Kockerling F, Reymond MA, Altendorf-Hofmann A et al. Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol 1998; 16: 324-329.
5. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl J Med 2001; 345: 638-646.
6. Lee JH, Lee JH, Ahn JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A preliminary report. J Clin Oncol 2002; 20: 1751-1758.
7. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
8. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
9. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
10. Blackstock AW, Hess S, Chaney S et al. Oxaliplatin: In vitro evidence of its radiation sensitizing activity. Pre-clinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 1999; 45: 253-254.
11. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
12. Crane CH, Skibber JM, Birnbaum EH et al. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2003; 57: 84-89.
13. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
14. Janjan NA, Crane C, Feig BW et al. Improved survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001; 24: 107-112.
15. Mohiuddin M, Hayne M, Regine WF et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000; 48: 1075-1080.
16. Freyer G, Bossard N, Romestaing P et al. Addition of oxaliplatin to continuous fluorouracil l-folinic acid and concomitant radiotherapy in rectal cancer: The Lyon R97-03 phase I trial. J Clin Oncol 2001; 19: 2433-2438.
17. Carraro S, Roca EL, Cartelli C et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54: 397-402.
18. Gérard JP, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 Phase II Trial. J Clin Oncol 2003; 21: 1119-1124.
19. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1098.
20. O'Connell MJ, Martenson JA, Wiecind HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507.
21. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232.
22. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
23. Arbuck SG, Ivy SP, Setser A et al. The revised Common Toxicity Criteria: Version 2.0. CTEP Website (htpp://ctep.info.nih.gov).
24. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: Version 2.0 - An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
25. Fleming DI, Cooper SJ, Henson ED et al. AJCC Cancer Staging Manual, fifth edition. Philadelphia, PA: Lippincott-Raven 1997; 83-90.
26. Glynne-Jones R, Falk S, Maughan T et al. Results of preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in locally advanced rectal cancer: A pilot study. Proc Am Soc Clin Oncol 2000; 19: 310a (Abstr 1225).
27. Sebag-Montefiore D, Glynne-Jones R, Falk S et al. Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 2002; 21: 146a (Abstr 580).
28. Garufi C, Pietrangeli A, Brienza S et al. Electrophysiological evaluation of oxaliplatin neurotoxicity. Proc Am Soc Clin Oncol 1999; 18: 244a (Abstr 938).
29. Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003; 30 (Suppl 15): 5-13.
30. Extra JM, Marty M, Brienza S et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25 (Suppl 5): 13-22.
31. Pasetto LM, Lonardi S, Sartor L et al. Phase I study of weekly oxaliplatin (OXA) +5-fluorouracil continuous infusion (FU CI) in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 23: 312 (Abstr 3770).
32. Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
33. Pucciarelli S, Friso ML, Toppan P et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol 2000; 7: 38-44.
34. Cionini L, Manfredi B, Sainato A. Randomized study of postoperative chemotherapy after preoperative chemoradiation in locally advanced rectal cancer. Preliminary results. Eur J Cancer 2001; 37: S300 (Abstr 1107).
35. Aschele C, Vitali ML, Binda GA et al. A phase I study of uracil/tegafur (UFT) and oral leucovorin (LV)+weekly oxaliplatin (OXA) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 279 (Abstr 3637).
36. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
37. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
38. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.